EUCTR2008-007689-52-EE
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/20mg) Versus Switching to Rosuvastatin 10mg or Doubling the Statin Dose
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Merck & Co. Inc.
- 入组人数
- 800
- 状态
- 进行中（未招募）
- 最后更新
- 13年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Patients with diabetes mellitus (Type 1 or 2\) with cardiovascular disease, \>\=18 and \<80 years of age with inadequately controlled lipids, either statin/ezetimibe naïve or on an acceptable stable dose, and willing to maintain a cholesterol\-lowering and glucose\-lowering diet for the duration of the study. Baseline LDL\-C must be between \= 70 mg/dL (1\.81 mmol/L) and \= 160 mg/dL (4\.14 mmol/L), TG \= 400 mg/dL (4\.52 mmol/L), ALT/AST \= 2\.0 X ULN, and CK \= 3\.0 X ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •Patient is Asian, is hypersensitive/intolerant to any component of the study medication, has CHF NYHA Class III or IV, is an uncontrolled hypertensive or diabetic, or is actively trying to lose weight. Prohibited medications include CYP3A4 inhibitors, lipid\-lowering agents, systemic corticosteroids, anti\-obesity medications, warfarin, or medications that could increase the risk of myopathy.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
The study is to evaluate the effectiveness and safety of switching to coadministration ezetimibe and atorvastatin compared with doubling the dose of atorvastatin or switching to rosuvastatin in patients with primary hypercholesterolemia and high cardiovascular risk who are not adequately controlled with atorvastatin 10 mg. Ezetimibe, atorvastatin and rosuvastatin are each available by prescription to treat high blood cholesterol levels.EUCTR2009-015247-16-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,508
进行中（未招募）
不适用
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin - SWITCHEUCTR2009-015247-16-SKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,508
进行中（未招募）
1 期
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS). - IN-CROSSEUCTR2006-005513-35-LTMerck&co., Inc.1,200
进行中（未招募）
1 期
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10mg/20mg) compared to Rosuvastatin 10mg in patients with primary hypercholesterolemia and high cardiovascular risk and not adequately controlled with a prior statin treatment. (IN-CROSS).EUCTR2006-005513-35-NL300
进行中（未招募）
1 期
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy - CANTATA-D2EUCTR2010-020053-14-BEJanssen-Cilag International NV720